natgillin/translations-raw huggingface dataset:
Med 131 bolniki, ki so se odzvali na indukcijo z ustekinumabom in so bili na začetki vzdrževalne študije randomizirani v skupino, ki je prejemala placebo, jih je 51 izgubilo odziv na zdravljenje in so prešli na subkutano odmerjanje 90 mg ustekinumaba na 8 tednov.
Of 131 patients who responded to ustekinumab induction, and were randomized to the placebo group at the start of the maintenance study, 51 subsequently lost response and received 90 mg ustekinumab subcutaneously every 8 weeks.
Med 4-tedenskim ciklom zdravljenja
During a 4-week cycle of treatment
Med absolutnimi vrednostmi intervala QTcF oziroma spremembo od izhodiščnih vrednosti in največjo koncentracijo sestavin zdravila Teysuno v plazmi niso opazili stalne povezave.
No consistent relationship was seen between absolute QTcF interval values or change from Baseline values and maximum plasma concentration of Teysuno components.
Med bolniki, ki so v kliničnih študijah prejemali zdravilo Pravafenix, je incidenca pomembnih zvišanj kreatin- fosfokinaze (KF ≥ 3-kratnika ZMN < 5-kratnika ZMN) znašala 1,92 %.
In clinical studies, the incidence of important elevations in creatine phosphokinase (CK ≥ 3 times the ULN, < 5 times the ULN) was 1.92% for patients treated with Pravafenix.
Med bolniki, ki so v kliničnih študijah prejemali zdravilo Pravafenix, je incidenca pomembnih zvišanj serumskih transaminaz (ALT in/ali AST ≥ 3-kratnika ZMN < 5-kratnika ZMN) znašala 0,83 %.
and/or AST ≥ 3 times the ULN, < 5 times the ULN) was 0.83% for patients treated with Pravafenix.
med brejostjo ali laktacijo,
if your dog is pregnant or during lactation
Med ciklom zdravljenja se mora odmerek prilagoditi za vsako posamezno zdravilo, za katero se ugotovi vzročna povezava s toksičnostjo.
During a treatment cycle, dose adjustment should be performed for each individual medicinal product that is considered to be causally related to the toxicity, if such a distinction can be made.
Med dolgotrajnim podaljšanjem 2. študije psoriaze pri odraslih (PHOENIX 2) je bil imunski odziv (pri bolnikih, ki so se zdravili z zdravilom STELARA vsaj 3,5 let) tako na pnevmokokne polisaharide kot na cepivo proti tetanusu podoben kot v kontrolni skupini bolnikov s psoriazo, ki niso prejemali sistemskega zdravljenja.
During the long term extension of Psoriasis Study 2 (PHOENIX 2), adult patients treated with STELARA for at least 3.5 years mounted similar antibody responses to both pneumococcal polysaccharide and tetanus vaccines as a non-systemically treated psoriasis control group.
Med kliničnimi preskušanji s topotekanom so poročali o smrtnih izidih zaradi nevtropeničnega kolitisa.
Fatalities due to neutropenic colitis have been reported in clinical trials with topotecan.
Med kliničnimi preskušanji so o izpuščaju poročali pri 4 % bolnikov in o pruritusu pri 1,5 % bolnikov.
In clinical trials, rash was reported in 4 % of patients and pruritus in 1.5 % of patients.
Med kliničnimi preskušanji so topotekan prenehali uporabljati, če je bil odmerek že zmanjšan na 1,0 mg/m2 in ga je bilo treba zaradi neželenih učinkov še dodatno zmanjšati.
In clinical trials, topotecan was discontinued if the dose had been reduced to 1.0 mg/m2 and a further dose reduction was required to manage adverse effects.
Med kliničnimi študijami s pemetreksedom so poročali o redkih primerih potencialno resnega hepatitisa.
Rare cases of hepatitis, potentially serious, have been reported during clinical studies with pemetrexed.
Med neželenimi učinki, ki se zelo pogosto (pri več kot 1 od 10 bolnikov) pojavijo pri zdravljenju z zdravilom INOmax, so: majhno število trombocitov.
Side effects that are very commonly seen (affects more than 1 user in 10) in association with INOmax therapy include:
Med obema odmerkoma zoledronske kisline ni bilo statistično značilnih razlik.
There were no statistically significant differences between the two zoledronic acid doses.
Med obroki pijte veliko tekočine, da nadomestite izgubljeno tekočino in da preprečite dehidracijo, znižanje volumna krvi in neravnovesje soli ali kemičnih snovi v krvi.
Take plenty of liquids between meals to replace lost fluids and prevent dehydration, low blood volume, and imbalance of salts or chemicals in the blood.
Med občasne neželene učinke (pojavijo se lahko pri 1 do 10 od 1.000 bolnikov) so vključeni:
Uncommon side effects (may affect 1 to 10 in 1,000 people) include:
Med pogoste neželene učinke (pojavijo se lahko pri 1 do 10 od 100 bolnikov) so vključeni:
Common side effects (may affect 1 to 10 in 100 people) include:
Med preizkušene polimere, ki jih lahko uporabimo pri sistemih za dovajanje dušikovega oksida, spadata polietilen (PE) in polipropilen (PP).
Tested polymers which can be used in nitric oxide administration systems include polyethylene (PE) and polypropylene (PP).
Med premeščanjem bolnikov, ki prejemajo zdravilo INOmax, znotraj bolnišnice ali med bolnišnicami morajo biti jeklenke trdno nameščene v pokončen položaj, da bi preprečili padce ali neprimerno spremembo dovajanja.
During inter- or within-hospital transfers of patients treated with INOmax, the gas cylinders should be fixedly stowed away in order to hold the gas cylinders vertically and to avoid the risk of fall or untimely modifying output.
Med presnovki se je 9,5–9,7 % prejetega tegafurja izločilo z urinom kot 5-FU in približno 70–77 % kot FBAL, kar ustreza približno 83–91 % prejetega odmerka zdravila Teysuno (skupno tegafur + 5-FU + FBAL).
Among the metabolites, 9.5% to 9.7% of the administered tegafur was excreted in the urine as 5-FU and approximately 70% to 77% as FBAL, accounting for approximately 83% to 91% of the administered Teysuno dose (total tegafur + 5-FU + FBAL).
Med primerjavo farmakokinetičnih parametrov nismo ugotavljali razlik med farmakokinetičnimi podatki v 5 dneh uporabe topotekana.
Comparison of pharmacokinetic parameters did not suggest any change in pharmacokinetics over the 5 days of dosing.
Med primerjavo farmakokinetičnih parametrov nismo ugotavljali razlik med farmakokinetičnimi podatki v petih dneh uporabe topotekana.
Comparison of pharmacokinetic parameters did not suggest any change in pharmacokinetics over the 5 days of dosing.
Med pripravo pred začetkom zdravljenja se prepričajte, da nastavitev naprave ustreza koncentraciji plina v jeklenki.
Before initiation of therapy, during set-up, secure that the device setting is in agreement with the cylinder gas concentration.
Med redke (pojavijo se lahko pri 1 do 10 od 10.000 bolnikov) in zelo redke neželene učinke (pojavijo se pri manj kot 1 od 10.000 bolnikov) so vključeni:
Rare side effects (may affect 1 to 10 in 10,000 people) and very rare side effects (may affect less than 1 in 10,000 people) include:
Med simptomi in znaki so lahko dispneja, neproduktiven kašelj in poslabšanje splošnega zdravstvenega stanja (utrujenost, hujšanje in vročina).
Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever).
Med skupinama ni bilo statistično značilne razlike v deležih krvavitev s smrtnim izidom (1,1 % klopidogrel + acetilsalicilna kislina, 0,7 % placebo + acetilsalicilna kislina) in hemoragičnih možganskih kapi (0,8 % v prim. z 0,6 %).
There was no statistically significant difference in the rates of fatal bleeding (1.1% in the clopidogrel + ASA group and 0.7% in the placebo +ASA group) and haemorrhagic stroke (0.8% and 0.6%, respectively) between groups.
Med skupinama ni bilo značilnih razlik v primarnem sestavljenem opazovanem dogodku, ki je obsegal smrt, trombozo spoja ali srčno intervencijo pred starostjo 120 dni po dogodku, za katerega je bilo ocenjeno, da je trombotične narave: v skupini s klopidogrelom je bilo takšnih 89 (19,1 %) in v skupini s placebom 90 (20,5 %) (glejte poglavje 4.2).
There was no significant difference between groups in the primary composite endpoint of death, shunt thrombosis or cardiac-related intervention prior to 120 days of age following an event considered of thrombotic nature (89 [19.1%] for the clopidogrel group and 90 [20.5%] for the placebo group) (see section 4.2).
Med spremljanjem bolnika s psoriazo mora biti zdravnik pozoren na simptome eritrodermične psoriaze ali eksfoliativnega dermatitisa.
As part of the monitoring of the patient’s psoriasis, physicians should be alert for symptoms of erythrodermic psoriasis or exfoliative dermatitis.
Med tem dolgoročnim spremljanjem niso ugotovili novih težav ali zadržkov v zvezi z varnostjo.
No new safety concerns were noted during this long-term follow-up.
Med temi 51 bolniki jih je 16 tednov po prejemu prvega subkutanega odmerka ustekinumaba 70,6% doseglo klinični odziv in 39,2% klinično remisijo.
Of these 51 patients, 70.6% achieved clinical response and 39.2% percent achieved clinical remission 16 weeks after receiving the first subcutaneous dose of ustekinumab.
Med uporabo zdravila Stelara morate biti pozorni na znake okužbe, ki vključujejo:
You must look out for signs of infection while you are using Stelara.
Med uporabo zdravila Stelara vam ne smejo dati nekaterih cepiv (živa cepiva).
Some types of vaccines (live vaccines) should not be given while using Stelara.
Med vožnjo motornih vozil ali delom s stroji pa se je treba zavedati, da se lahko med zdravljenjem pojavijo vrtoglavica ali motnje vida.
However, when driving vehicles or using machines, it should be taken into account that dizziness and visual disturbances may occur during treatment.
Med zdravili, ki zavirajo CYP2C19, so omeprazol in esomeprazol, fluvoksamin, fluoksetin, moklobemid, vorikonazol, flukonazol, tiklopidin, ciprofloksacin, cimetidin, karbamazepin, okskarbazepin in kloramfenikol.
Medicinal products that inhibit CYP2C19 include omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, ciprofloxacin, cimetidine, carbamazepine, oxcarbazepine and chloramphenicol.
Med zdravljenjem s pemetreksedom morajo ženske uporabljati učinkovito metodo kontracepcije.
Women must use effective contraception during treatment with pemetrexed.
Med zdravljenjem s topotekanom so pri približno 25 % bolnikov opazili utrujenost, pri 16 % pa astenijo.
Fatigue was observed in approximately 25 % and asthenia in 16 % of patients whilst receiving topotecan.
Med zdravljenjem vam bo dal prvi odmerek zdravila Stelara, približno 6 mg/kg, vaš zdravnik v obliki kapljične infuzije v eno od ven na roki (intravenska infuzija).
During treatment, the first dose of approximately 6 mg/kg Stelara will be given by your doctor through a drip in a vein in your arm (intravenous infusion).
Med zdravljenjem z difosfonati so bili opisani atipični subtrohanterni in diafizni zlomi stegnenice, predvsem pri bolnikih, ki so prejemali dolgotrajno zdravljenje za osteoporozo.
Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, primarily in patients receiving long-term treatment for osteoporosis.
Med zdravljenjem z difosfonatom je treba bolnikom naročiti, naj povedo za vsako bolečino v stegnu, kolku ali dimljah, bolnike, ki imajo takšne simptome, pa je treba oceniti glede nepopolnega zloma stegnenice.
During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.
Med zdravljenjem z zdravilom Teysuno in do 6 mesecev po zdravljenju morate uporabljati učinkovito kontracepcijo.
During and up to 6 months after treatment with Teysuno, you must use contraceptive measures.
Med zdravljenjem z zdravilom Teysuno je treba prenehati z dojenjem.
Breast-feeding must be discontinued while receiving treatment with Teysuno.
Med zdravljenjem z zdravilom Topotekan Teva ne smete dojiti.
You must not breast-feed while on treatment with Topotecan Teva.
Med zelo pogoste neželene učinke (pojavijo se lahko pri več kot 1 od 10 bolnikov) so vključeni:
Very common side effects (may affect more than 1 in 10 people) include:
Med zelo pogoste neželene učinke (pojavijo se lahko pri več kot 1 od 10 bolnikov) so vključeni:
Very common side effects (may affect more than 1 in 10people) include:
Meda AB
Meda AB.
Meda AB Pipers väg 2A 170 09 Solna Швеция
Meda AB Pipers väg 2A S-170 09 Solna Sweden
Meda Health Sales Ireland Limited Unit 34/35, Block A
Meda Health Sales Ireland Ltd.
MEDA Manufacturing GmbH, Neurather Ring 1,
MEDA Manufacturing GmbH Neurather Ring 1
MEDA Pharma GmbH Guglgasse 15
Meda Pharmaceuticals Sp.z.o.o. ul.
MEDA PHARMA Hungary Kereskedelmi Kft.
Alfred Gera & Sons Ltd.
Meda Pharma SIA Ukmergės street 369A LT-- 12142 Vilnius
Meda Pharma SIA Ukmergės street 369A LT- 12142 Vilnius
Meda Pharmaceuticals Sp.z.o.o.
Meda Pharmaceuticals Sp. z o.o.
MEDA Pharmaceuticals Switzerland GmbH, Podružnica Ljubljana
MEDA Pharmaceuticals Switzerland GmbH Podružnica Ljubljana
MEDA Pharmaceuticals Switzerland GmbH, представителство за България
MEDA Pharmaceuticals Switzerland GmbH представителство за България
Medan du tar Emtriva kan du fortfarande utveckla infektioner eller andra sjukdomar som förknippas med hiv-infektion.
While taking Emtriva you may still develop infections or other illnesses associated with HIV infection.
MedDRA
Common
MedDRA = Медицински речник за регулаторни дейности: SMQ = Стандартизирано запитване по MedDRA
MedDRA = Medical Dictionary for Regulatory Activities: SMQ = Standardized MedDRA Query
MedDRA Предпочитан термин
MedDRA Preferred Term
MedDRA Системо- органен клас
MedDRA System Organ Class
MedDRA Стандартни Системо- органни класове
MedDRA Standard System Organ Class
MedDRA Стандартни системо-органни класове
MedDRA Standard System Organ Class
MedDRA системно- органни класове
MedDRA System organ class
MedDRA системо органни класове
MedDRA system organ classes
MedDRA системо органни класове
MedDRA system srgan classes
MedDRa системо- органен клас
MedDRa system organ class
MedDRA системо- органни класове
MedDRA system
MedDRA системо- органни класове
MedDRA System organ class
MedDRA системо- органни класове
MedDRA system organ classes
MedDRA системо-органен клас
MedDRA system organ class
MedDRA системо-органен клас (V.14.0) Инфекции и инфестации
Infections and infestations
MedDRA системо-органен клас (V.14.0) Инфекции и инфестации
MedDRA system organ class (V.14.0)
MedDRA системо-органни класове
MedDRA System organ class
MedDRA стандартни системо-органни класове
MedDRA Standard System Organ Class
MedDRA  Медицински речник за регулаторни дейности (Medical Dictionary for Regulatory Activities).
MedDRA  Medical Dictionary for Regulatory Activities.
MedDRA-база данни на системо-органни класове
MedDRA system organ classes
MedDRAсистемо-органни класове
MedDRA system organ classes
Medelkoncentrationsförhållandet mellan plasma och blod var cirka 1,0 och medelkoncentrationsförhållandet mellan sädesvätska och plasma cirka 4,0.
The mean plasma to blood concentration ratio was approximately 1.0 and the mean semen to plasma concentration ratio was approximately 4.0.
Median DR3,4 (месеци) [диапазон5]
(Months) [Range5]
Median PFS (месеци) (95% CI)
Median PFS (months) (95% CI)
Mediana
Median
Mediana (95-% IZ), meseci
Median [95% CI], months
Mediana (95-% IZ), meseci
Median [95% CI]. months
Mediana (m)
Median (m)
Mediana razpolovna doba v vseh starostnih skupinah skupaj je bila 29,5 ure, v posameznih starostnih skupinah pa je bila po dajanju 20 µg/kg v mejah od okrog 20 do 30 ur.
Median half-life was 29.5 hours in overall age groups and ranged from about 20 to 30 hours across age groups after administration of 20 μg/kg.
Mediana skupnega preživetja v mesecih (95 % IZ)
Median overall survival in months (95% CI)
Mediana skupnega preživetja za celotno populacijo (N = 663) je bila 13,4 mesece za skupino s pemetreksedom in 10,6 mesecev za skupino s placebom, razmerje tveganja = 0,79 (95 % CI: 0,65 do 0,95; p = 0,01192).
10.6 months for the placebo arm, hazard ratio = 0.79 (95% CI= 0.65-0.95, p = 0.01192).
Mediana Tmax za 5-FU je znašala 2,0 ure, povprečje AUC(0-12h) in Cmax pa 870 ± 405 ng.hr/ml in 165 ± 62 ng/ml, in sicer v tem zaporedju.
The median Tmax for 5-FU was 2.0 hours and the mean AUC(0-12h) and Cmax was 870 ± 405 ng.hr/ml and 165 ± 62 ng/ml, respectively.
Mediana Tmax za 5-FU je znašala 2,0 ure, povprečje AUC0-inf in Cmax pa 842 ± 252 ng.hr/ml in 174 ± 58 ng/ml.
The median Tmax for 5-FU was 2.0 hours and the mean AUC0-inf and Cmax was 842 ± 252 ng.hr/ml and 174 ± 58 ng/ml.
Mediana vrednost (95 % IZ)
Median (95% C.I.)
Mediana vrednost najnižje serumske koncentracije ustekinumaba pri bolnikih z večjo telesno maso (> 100 kg) v skupini za odmerek 90 mg je bila podobna kot pri bolnikih z manjšo telesno maso (≤ 100 kg) v skupini za prejemanje 45 mg odmerka.
The median trough serum concentrations of ustekinumab in patients with higher weight (> 100 kg) in the 90 mg group were comparable to those in patients with lower weight (≤ 100 kg) in the 45 mg group.
Mediana vrednost porazdelitvenega volumna v končni fazi (Vz) po enkratni intravenski injekciji zdravila bolnikom s psoriazo je bila od 57 do 83 ml/kg.
Median volume of distribution during the terminal phase (Vz) following a single intravenous administration to patients with psoriasis ranged from 57 to 83 mL/kg.
Mediana vrednost razpolovnega časa (t1/2) ustekinumaba pri bolnikih s Crohnovo boleznijo, psoriazo in/ali psoriatičnim artritisom je znašala približno 3 tedne in se je gibala v razponu od 15 do 32 dni v vseh študijah psoriaze in psoriatičnega artritisa.
Median half-life (t1/2) of ustekinumab was approximately 3 weeks in patients with Crohn’s disease, psoriasis and/or psoriatic arthritis, ranging from 15 to 32 days across all psoriasis and psoriatic arthritis studies.
Mediana vrednost razpolovnega časa (t1/2) ustekinumaba pri bolnikih s psoriazo, psoriatičnim artritisom ali Crohnovo boleznijo je znašala približno 3 tedne in se je gibala v razponu od 15 do 32 dni v vseh študijah psoriaze in psoriatičnega artritisa.
Median half-life (t1/2) of ustekinumab was approximately 3 weeks in patients with psoriasis, psoriatic arthritis or Crohn’s disease, ranging from 15 to 32 days across all psoriasis and psoriatic arthritis studies.
Mediana vrednost sistemskega očistka (CL) ustekinumaba pri bolnikih s psoriazo po enkratnem intravenskem injiciranju je bila od 1,99 do 2,34 ml/dan/kg.
Median systemic clearance (CL) following a single intravenous administration to patients with psoriasis ranged from 1.99 to 2.34 mL/day/kg.
Mediana vrednost sistemskega očistka (CL) ustekinumaba, pri bolnikih s psoriazo, po enkratnem intravenskem injiciranju je bila od 1,99 do 2,34 ml/dan/kg.
Median systemic clearance (CL) following a single intravenous administration to patients with psoriasis ranged from 1.99 to 2.34 mL/day/kg.
Mediana časa do napredovanja tumorja (meseci)
Median time to tumour progression (months)
Mediane vrednosti tmax za ustekinumab, po enkratni subkutani injekciji bodisi 45 mg ali 90 mg zdravila, pri bolnikih s psoriazo so bile podobne kot pri zdravih preizkušancih.
The median tmax values of ustekinumab following a single subcutaneous administration of either 45 mg or 90 mg in patients with psoriasis were comparable to those observed in healthy subjects.
Mediani čas do normokalciemije je bil 4 dni.
Median time to normocalcaemia was 4 days.
Mediani čas do SRE (dnevi)
Median time to SRE (days)
Medical Need Europe AB Tel: + 46 8 533 39 500
Medical Need Europe AB Tel: + 46 8 533 39 500 info@medicalneed.com
Medice Arzneimittel Pütter GmbH & Co KG, Kuhloweg 37, D-58638 Iserlohn, Германия
Medice Arzneimittel Pütter GmbH & Co KG, Kuhloweg 37, D-58638 Iserlohn, Germany
Medicinal Oxygen Air Liquide Santé 100 % инхалационен газ за кучета, котки и коне
Medicinal Oxygen Air Liquide Santé 100 % inhalation gas for dogs, cats and horses.
Medicinal Oxygen Air Liquide Santé е инхалационен газ, който се сьстои от 100 % кислород.
Medicinal Oxygen Air Liquide Santé is an inhalation gas consisting of 100 % oxygen.
Medicinal Oxygen Air Liquide Santé може да бьде използван по време на бременност и лактация
Medicinal Oxygen Air Liquide Santé can be used during pregnancy and lactation.
Medicinal product no ger
Medicinal product no longerh
Medicinal product no longer authorised
List of excipients
Medicinal product no longer authorised
Marketing authorisation holder: Zoetis Belgium SA
Medicinski izdelki, ki zmanjšujejo strjevanje krvi, vazokonstrikcijo ali agregacijo trombocitov, npr. inhibitorji tromboksana A2, bi lahko zmanjšali učinkovitost PDT.
Medicinal products that decrease clotting, vasoconstriction or platelet aggregation, e.g., thromboxane A2 inhibitors, could decrease the efficacy of PDT.
MedImmune Pharma BV Lagelandseweg 78 6545 CG Nijmegen, Нидерландия
MedImmune Pharma BV Lagelandseweg 78 6545 CG Nijmegen, The Netherlands.
MedImmune, UK Limited Plot 6, Renaissance Way Boulevard Industry Park Speke,
MedImmune UK Limited Plot 6, Renaissance Way Boulevard Industry Park Speke,
Medián terminálního poločasu kobicistatu v plazmě po podání kobicistatu je přibližně 3-4 hodiny.
The median terminal plasma half-life of cobicistat following administration of cobicistat is approximately 3-4 hours.
Medián výchozí plazmatické hodnoty HIV-1 RNA byl 4,81 log10 kopií/ml (rozpětí: 3,21-6,44).
The median baseline plasma HIV-1 RNA was 4.81 log10 copies/ml (range: 3.21-6.44).
Medián věku subjektů byl 36 let (rozpětí: 19-70).
The median age of subjects was 36 years (range: 19-70).
Medsebojna delovanja, ki so skupna vsem citotoksičnim zdravilom
Interactions common to all cytotoxics
Medsebojno delovanje s hrano
Food interaction
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Interaction with other medicinal products and other forms of interaction
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Interactions with other medicinal products and other forms of interaction
Medtem ko nekatere simptome brez težav prepoznajo kot neželene učinke že sami bolniki, je za identifikacijo določenih simptomov treba opraviti krvni test.
While some symptoms are easily identified as side effects by the patients themselves, a blood test is required to identify some other symptoms.
Medzipacientská variabilita populačného odhadu u plazmatického klírensu trabektedínu bola 49 % a medzipacientská variabilita bola 28 %.
The inter-patient variability of the population estimate for plasma clearance of trabectedin was 49% and intra-patient variability was 28%.
Meget almindelig (mere end 1 ud af 10 dyr, der viser bivirkning(er) i løbet af en behandling)
very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment)
meget almindelige (mere end 1 ud af 10 dyr får bivirkninger i løbet af en behandling)
very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
Meglumin
Meglumine
Meglumin
None known.
Mehanizem večje incidence atrijske fibrilacije v tem enem kliničnem preskušanju ni znan.
The mechanism behind the increased incidence of atrial fibrillation in this single clinical trial is unknown.
Meibergdreef 61, 1105 BA Амстердам, Нидерландия.
Meibergdreef 61, 1105 BA Amsterdam, The Netherlands.
MEK протеините са компоненти на пътя на киназа, регулируема от извънклетъчни сигнали (extracellular signal-related kinase, ERK).
MEK proteins are components of the extracellular signal-related kinase (ERK) pathway.
MEK115306 (COMBI-d)
MEK115306 (COMBI-d):
MEK115306 е рандомизирано, двойносляпо проучване фаза III, сравняващо комбинацията дабрафениб и траметиниб с дабрафениб и плацебо като първа линия терапия при участници с нерезектабилен (Стадий IIIC) или метастатичен (Стадий IV) позитивен за BRAF V600E/K мутация кожен меланом.
MEK115306 was a Phase III, randomised, double-blinded study comparing the combination of dabrafenib and trametinib to dabrafenib and placebo in first-line therapy for subjects with unresectable (Stage IIIC) or metastatic (Stage IV) BRAF V600E/K mutation-positive cutaneous melanoma.
MEK116513 (COMBI-v)
MEK116513 (COMBI-v):
Mekanismen är inte känd.
The mechanism is unknown.
mekinist 0,5 mg
mekinist 0.5 mg
Mekinist 0,5 mg филмирани таблетки EU/1/14/931/001
Mekinist 0.5 mg film-coated tablets EU/1/14/931/001
Mekinist 0,5 mg филмирани таблетки Mekinist 2 mg филмирани таблетки
Mekinist 0.5 mg film-coated tablets Mekinist 2 mg film-coated tablets
Mekinist 0,5 mg филмирани таблетки Ядро на таблетката
Mekinist 0.5 mg film-coated tablets Tablet core